Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joel Unowsky is active.

Publication


Featured researches published by Joel Unowsky.


Chemotherapy | 1988

Enteral, Oral, and Rectal Absorption of Ceftriaxone Using Glyceride Enhancers

George Beskid; Joel Unowsky; Charanjit Rai Behl; Jo Ann Siebelist; Jacques Levon Tossounian; Carolyn M. McGarry; Navnit Shah; Roy Cleeland

In vivo models in rodents and primates were used to investigate ways of overcoming the poor oral and rectal absorption of ceftriaxone. The sodium salt of ceftriaxone at 20 mg/kg was formulated in C8-C10 chain length, mono- and diglyceride extracts of coconut oil (Capmul) and administered intraduodenally to adult rats. Peak plasma levels of 17-52 micrograms/ml and bioavailability averaging 38% were attained. Significant plasma levels (42-45 micrograms/ml) were also demonstrated in squirrel monkeys with doses of 20 mg/kg ceftriaxone formulated in Capmul and given by the enteral route. Enteric-coated capsules containing this formulation were also orally administered to squirrel monkeys and gave high plasma levels (10-31 micrograms/ml) between 1 and 6 h following dosing. In rectal absorption studies, ceftriaxone formulated in Capmul as a suspension gave peak blood levels of 62-84 micrograms/ml (average bioavailability 42%) in the rabbit. In the baboon, rectal administration of ceftriaxone formulated with Capmul in a Witepsol H15 suppository gave Cmax levels ranging from 9 to 48 micrograms/ml, depending on the dose of the antibiotic and the drug/enhancer ratio.


Critical Reviews in Microbiology | 1982

Correlation of the Results of Antibiotic Synergy and Susceptibility Testing in Vitro with Results in Experimental Mouse Infections

Henry D. Isenberg; Jane Sampson-Scherer; Roy Cleeland; Edith Titsworth; George Beskid; James Gordon Christenson; William DeLorenzo; Joel Unowsky

Recent clinical isolates (approximately 150 strains) of the family Enterobacteriaceae were examined by agar diffusion, microdilution, and the Autobac automated system for their responses to beta-lactam antibiotics singly and in combination with amdinocillin (formerly called mecillinam). The ratio of ampicillin, carbenicillin, and cephalothin to amdinocillin was maintained at a 10:1 ratio in most of the evaluations. The same isolates were studied in mice challenged with 100 to 1000 LD50s and treated with graded doses of the antibiotics singly and in combination. Efficacy in vivo was based on the concentration of antibiotic in milligrams per kilograms (mg/kg) required to protect 50% of the animals (PD50). After a single administration of the antibiotics, plasma levels were determined in the critical time period (30 min to 4 hr) during which the acute, overwhelming systemic infections could be controlled by appropriate therapy. Regression curves comparing in vivo and in vitro results were used to establish cut-off points for categorizing bacterial susceptibility in each of the laboratory tests for the single agents and combinations. A high degree of synergism between amdinocillin and the beta-lactam agents was demonstrated in animals (54 to 78% of the strains examined) and to a lesser extent by laboratory methodologies. There was an excellent correlation of in vivo and in vitro responses to ampicillin, carbenicillin, and cephalothin alone and in combination with amdinocillin for those species for which the single antibiotics are generally indicated. The correlations validated the chosen cut-off points. The correlation of in vivo and in vitro responses to the single or combined antibiotics was generally poorer for those species not usually responsive to the single antibiotics. The greatest difficulty in predicting proper in vivo responses, based on the results of in vitro tests, was observed with amdinocillin.


Chemotherapy | 1988

Effect of Medium Chain Glycerides on Enteral and Rectal Absorption of β-Lactam and Aminoglycoside Antibiotics

Joel Unowsky; Charan R. Behl; George Beskid; Joan Sattler; Judith Halpern; Roy Cleeland

The rat enteral and rabbit rectal models were utilized to study the effect of Capmul (medium chain glycerides) on the absorption of a selection of beta-lactam and aminoglycoside antibiotics. All tested non-orally available beta-lactam antibiotics (cefamandole, cefotaxime, moxalactam, cefoxitin, mezlocillin, carumonam, penicillin G and amdinocillin) showed increased absorption enterally in rats and rectally in rabbits when formulated with Capmul. The orally available beta-lactam antibiotics, cephalexin and cephradine, were not enhanced in their enteral or rectal absorption by Capmul in the two model systems. Ampicillin absorption was enhanced rectally and enterally by Capmul. Rectal absorption of the aminoglycoside antibiotics, tobramycin and gentamycin, was enhanced by Capmul while enteral absorption was not.


Chemotherapy | 1986

In vitro and in vivo activity of coumermycin and other antibacterial agents against methicillin-resistant strains of Staphylococcus aureus.

Joel Unowsky; Pranatharth H. Chandrasekar; William DeLorenzo; Donald P. Levine

The in vitro activity of coumermycin, fusidic acid, cotrimoxazole, and vancomycin was determined by broth microdilution assay against 33 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates from the Detroit Receiving Hospital, Detroit, Mich. Coumermycin was the most active drug tested, while fusidic acid, vancomycin, and cotrimoxazole also had good activity. The four antimicrobials were tested in vivo against 7 strains of MRSA employing the mouse protection model. Again, coumermycin was the most active, followed by vancomycin, cotrimoxazole, and fusidic acid. Coumermycin was very active, while vancomycin and fusidic acid were inactive in neutropenic mice infected with an MRSA strain. Coumermycin retained activity when given 18 h before an MRSA infection, while vancomycin activity was lost. Coumermycin was active in a local thigh infection while vancomycin was inactive. The results indicate that coumermycin is potent against MRSA with activity equal or superior to comparable agents in various experimental mouse infections.


Biotherapy | 1989

Stimulation of hematopoiesis and antibacterial resistance by interleukin-1.

Kim W. McIntyre; Joel Unowsky; William DeLorenzo; Nadine Tare; Joseph M. Plocinski; William R. Benjamin

SummaryThe beneficial effects of IL-1 and other cytokines on hematopoiesis and on resistance to infection are profound. IL-1 stimulates proliferation of bone marrow cells in normal mice and potentiates the recovery of peripheral blood neutrophils in mice with drug-induced neutropenia. Prophylactic cytokine administration provides an elevated level of natural resistance to infections which is correlated with increased numbers of phagocytic leukocytes. These studies suggest that IL-1 has potential clinical application as a therapy to limit bone marrow dysfunction and immuno-suppression and to augment hematopoiesis and natural immunity. Further research will continue to elucidate the mechanisms whereby interleukins and colony-stimulating factors act, and interact, to promote restoration of leukocyte production and to enhance host resistance.


Chemotherapy | 1989

Potencies of Ceftriaxone and Cefotaxime in a Single Chamber Pharmacokinetic System Simulating Their in vivo Half-Lives1

Joel Unowsky; Sattler J; Patel Ih

Ceftriaxone and cefotaxime are third-generation cephalosporins with similar in vitro potencies and spectra. However, previous studies have shown that ceftriaxone had superior in vivo activity (mouse PD50 values greater than or equal to 2-fold lower) compared to cefotaxime in 23 of 46 tested enterobacteriaceae. This superior activity was thought to be due to ceftriaxones 5- to 8-fold longer half-life. The relationship between half-life (ceftriax-one 6 h, cefotaxime 1 h) and potency was examined by following bacterial kill curves in a single chamber, open-ended perfusion model over an 8-hour period. Both antibiotics were compared for efficacy at both half-lives against four gram-negative bacteria. For two of the bacterial strains antibiotic potency differences in the perfusion model were determined largely by pharmacokinetics. For the other two strains intrinsic bacterial and antibiotic properties were of prime importance.


Archive | 1982

Enteric coated oral dosage form

Charanjit Rai Behl; George Beskid; Navnit Shah; Jacques Levon Tossounian; Joel Unowsky


Archive | 1991

Absorption enhancement of antibiotics

Maria Oksana Bachynsky; Martin Howard Infeld; Navnit Shah; Joel Unowsky


The Journal of Antibiotics | 1978

INCREASED PRODUCTION OF THE ANTIBIOTIC AURODOX (X-5108) BY AURODOX-RESISTANT MUTANTS

Joel Unowsky; Donald C. Hoppe


Archive | 2012

Oral dosage form

Charanjit Rai Behl; George Beskid; Navnit Shah; Jacques Levon Tossounian; Joel Unowsky

Collaboration


Dive into the Joel Unowsky's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge